NO Donors and Inhibitors to Study Imbalance of Nitrogen Stress and Antioxidant Defense in COPD

• Status: Completed
• Trial end date: 2006-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary aim of this study is to investigate the effects of oral and inhaled administration of L-arginine and of inhaled aminoguanidine on bronchial and alveolar exhaled NO and NO metabolites in exhaled breath condensate, induced sputum, nasal lavage and mouth wash fluid in healthy non-smokers, current smokers and patients with COPD.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Imperial College London
• Treatments: Nitric Oxide; Pimagedine

Criteria

Inclusion Criteria:

• Healthy non-smokers

• Normal spirometry (FEV1 >90 % predicted; exhaled NO bigger than or equal to 10 ppb; flow 50 ml/s)

• At risk (current smokers)

• Normal spirometry, with or without chronic symptoms (cough, sputum production)

• FEV1 reversibility of <15% after inhaled beta2-agonists*

• Moderate COPD

• FEV1 greater than or equal to 30% and < 80%

• FEV1/FVC < 70% predicted

• FEV1 reversibility of <15% after inhaled beta2-agonists

• With or without chronic symptoms (cough, sputum production, dyspnea)

• Able to comprehend and grant a written informed consent

Exclusion Criteria:

• Concomitant use or pre-treatment within the last 4 weeks with oral steroids

• Respiratory infection within 4 weeks prior to entry into the trial

• Females who are pregnant or lactating

• History of current or past drug or alcohol abuse